Aastrom Biosciences Inc., which develops stem cell-based tissue-regeneration products, said Wednesday its third-quarter loss widened 37 percent as expenses increased, and announced it can now start
making products at its German plant.
The Houston Chronicle
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Procleix’s Zika Assay Earns FDA Approval for Use With Panther System
The assay is also approved to test plasma or serum samples to screen other living or dead organ donors and human cells, tissues and cellular and tissue-based products.
FDA Plans Study of Risk Information in Direct-to-Consumer Print Ads
The in-person study will consist of an hour-long 40-person pilot study, in addition to two hour-long studies with 200 voluntary participants each.
FDAnews Drug Daily Bulletin
AASTROM 3Q LOSS WIDENS 37 PERCENT
May 11, 2006